Luveltamab Tazevibulin (STRO-002)

Luveltamab Tazevibulin · Sutro Biopharma, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Luveltamab Tazevibulin (STRO-002), covering 2025-08-24 to 2025-08-24. Get the full timeline:

Most recent: Clinical Trial Update: Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML [Phase 1, Phase 2]

See pricing